Clear cell renal cell carcinoma, noted for its frequent biallelic inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene, has long been a subject of intense study due to its complex metabolic rewiring and resistance to standard therapies. The loss of VHL function disrupts key regulatory circuits, significantly influencing cellular metabolism and substrate utilization. In this comprehensive study, the authors embarked on validating previously identified metabolomic signatures and teasing out metabolic predictors that correlate with patient responses to systemic treatments such as VEGF-tyrosine kinase inhibitors (VEGF-TKI) and immune checkpoint blockade (ICB).

The research team meticulously analyzed 52 paired tumor and normal kidney samples utilizing advanced metabolomic profiling techniques. This paired design allowed a controlled comparison, ensuring that intrinsic patient variability did not confound the differential metabolic landscape observed in ccRCC tissues. Using paired t-tests and unsupervised clustering algorithms, the researchers stratified tumors into four distinct metabolic subgroups, each characterized by unique metabolites and pathways.

One of the salient findings was the consistent activation of the upper glycolytic pathway and the pentose phosphate pathway (PPP) across tumor samples. These metabolic circuits are essential for providing cancer cells with the biosynthetic precursors and reducing equivalents necessary for rapid proliferation and survival under oxidative stress. The elevated glutamine levels detected further reinforce the notion that ccRCC cells shift towards glutamine addiction, fueling both anaplerosis and redox balance. Intriguingly, proteinogenic amino acids, other than glutamine, were found to be diminished, hinting at a selective metabolic remodeling that privileges certain substrates over others.

Despite prior reports emphasizing lactate accumulation as a hallmark of ccRCC metabolism, this investigation revealed a pronounced heterogeneity in lactate concentrations across the metabolic subgroups. This variability suggests that lactate production and clearance may be more nuanced than previously appreciated, potentially reflecting adaptation to microenvironmental conditions or divergent metabolic dependencies among tumor cells.

Further linking metabolism with pathophysiology, the metabolic clusters enriched with high-grade tumors exhibited decreased expression of vascular endothelial growth factor (VEGF) pathway-related genes. This observation is clinically relevant, as VEGF signaling is a pivotal mediator of angiogenesis in ccRCC, and its downregulation could impact both tumor aggressiveness and therapeutic targets.

Diving deeper into therapy-specific metabolomic alterations, the study analyzed specimens from patients treated with VEGF-TKI and immune checkpoint inhibitors separately. VEGF-TKI responders displayed distinctive decreases in certain fatty acid species, aligning with previous evidence that fatty acid metabolism may modulate angiogenic signaling and drug sensitivity. Conversely, patients responding to immune checkpoint blockade exhibited a unique metabolic fingerprint marked by depleted tryptophan and hydroquinone levels, alongside increases in metabolites such as pyruvic acid-oxime, 3-hydroxypropinoic acid, and hydroxylamine. These changes are particularly intriguing given the immunometabolic crosstalk underpinning anti-tumor immunity and the role of tryptophan metabolism in immune evasion.

The implications of these findings are manifold. By validating a robust metabolomic classification of ccRCC, this study not only augments our understanding of tumor biology but also underlines the utility of metabolic biomarkers for predicting patient response to diverse systemic therapies. Such biomarkers could be incorporated into clinical workflows to tailor treatments, optimize drug selection, and monitor efficacy non-invasively.

Methodologically, the integration of metabolomics with transcriptomic data and clinical parameters exemplifies a systems biology approach crucial for unraveling cancer heterogeneity. The four metabolic subgroups defined could serve as a foundation for future trials aimed at stratifying patients based on metabolic vulnerabilities, enhancing precision oncology strategies.

Moreover, the identification of differential fatty acid and amino acid metabolism in relation to therapeutic outcomes opens exciting prospects for metabolic reprogramming interventions. Targeting aberrant glutamine metabolism, modulating lactate production, or correcting amino acid imbalances might enhance the efficacy of existing treatments or overcome resistance mechanisms.

From a broader perspective, this research illustrates the increasingly recognized role of the tumor microenvironment and metabolic plasticity in cancer progression. ccRCC’s metabolic landscape is shaped not only by genetic mutations but also by the adaptive responses to hypoxia and nutrient availability, encapsulated by the VHL-driven changes elucidated here.

One cannot ignore the translational potential of these insights. As systemic therapies expand with novel agents entering the clinic, the ability to predict which patients will benefit most from VEGF-TKI or ICB regimens based on metabolomic signatures could revolutionize care paradigms, reduce unnecessary toxicity, and improve survival outcomes.

Furthermore, the study invites a reevaluation of lactate’s role as a universal biomarker in ccRCC. Given the diverse lactate levels observed, future investigations should explore the mechanisms governing lactate metabolism’s heterogeneity and its link to immune infiltration and stromal interactions.

In conclusion, this meticulous dissection of ccRCC’s metabolic landscape underscores how cancer cells orchestrate complex biochemical adaptations to flourish and evade therapy. The discovery of metabolite markers associated with drug response heralds a new era of metabolomics-driven oncology, wherein small molecules within the tumor milieu could become pivotal guides for therapeutic decision-making. It is an exciting time for cancer research, with metabolism emerging from the shadows to take center stage in the quest for more effective and personalized treatments.

Subject of Research: Metabolic profiling and classification of clear cell renal cell carcinoma with identification of metabolites predictive of response to systemic therapies.

Article Title: Metabolic landscape of clear cell renal cell carcinoma and search for metabolites predictive of drug response.

Article References:
Ozawa, M., Naito, S., Makinoshima, H. et al. Metabolic landscape of clear cell renal cell carcinoma and search for metabolites predictive of drug response.
BMC Cancer 25, 1357 (2025). https://doi.org/10.1186/s12885-025-14661-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14661-4

Keywords: Clear cell renal cell carcinoma, ccRCC, metabolomics, metabolic biomarkers, VHL gene, VEGF-TKI, immune checkpoint blockade, tumor metabolism, glycolysis, pentose phosphate pathway, glutamine metabolism, fatty acids, tryptophan metabolism, personalized oncology

For decades, the beneficial influence of regular physical activity on cancer incidence and progression has been recognized epidemiologically, yet the precise biochemical underpinnings remain shrouded in complexity. This study sheds light on a pivotal link between exercise-induced metabolic changes and tumor cell vulnerability, suggesting that lactate accumulation from muscle activity is not just a metabolic waste but an intricate signaling molecule capable of rewiring tumor metabolism at the cellular level.

Clear cell renal cell carcinoma, characterized by its notorious resistance to conventional therapies, represents a critical challenge in oncology. Its pathogenesis involves profound metabolic reprogramming, with tumor cells adapting to hypoxic conditions and altered nutrient availability—factors that drive unchecked proliferation and metastasis. Previous research has hinted at metabolic dependencies in ccRCC, but this new work advances the field by identifying a tangible connection between exercise-induced systemic factors and tumor intracellular metabolism.

Central to this discovery is the enzyme CNDP2, a dipeptidase that emerged as a crucial mediator in the metabolic crosstalk triggered by lactate exposure. The scientists demonstrated that lactate accumulation upregulates CNDP2 expression within ccRCC cells, which in turn catalyzes the breakdown of specific dipeptides, leading to a consequential depletion of intracellular amino acids. This amino acid scarcity disrupts critical biosynthetic and energy-generating pathways, essentially starving tumor cells and curbing their proliferation capacity.

The team employed a comprehensive array of experimental techniques, including in vitro tumor cell models, murine exercise regimens, and metabolomic profiling, to decode this intricate cascade. Their multifaceted approach confirmed that lactate derived from muscle activity elevates CNDP2 at both the mRNA and protein levels, and that this modification drastically alters the amino acid landscape inside cancer cells. Strikingly, this metabolic disruption renders ccRCC cells more susceptible to apoptosis and growth arrest.

In exploring the broader implications of their findings, the researchers also noted that the metabolic interference caused by CNDP2-mediated amino acid depletion intersects with key oncogenic signaling networks. Pathways such as mTOR and AMPK, known master regulators of cell growth and metabolism, appear affected by changes in amino acid availability, suggesting that exercise-generated lactate influences tumor biology through multi-layered regulatory nodes. This insight uncovers potential combinatorial strategies for adjunct therapies alongside physical exercise interventions.

Moreover, the study confronts long-standing dogmas concerning lactate’s role in cancer. Historically perceived largely as a byproduct of the “Warburg effect,” cancer cells were thought to rely heavily on glycolysis for rapid energy, thus producing excess lactate that promotes tumor aggressiveness and immune evasion. However, these results intriguingly depict lactate as a double-edged sword, capable of exerting antitumoral effects via distinct biochemical pathways, particularly in the context of systemic physiological states induced by exercise.

This revelation invites a reevaluation of metabolic therapies aimed at cancer. Rather than universally targeting lactate production or signaling, nuanced strategies could leverage controlled exercise regimens to exploit this natural metabolic vulnerability of ccRCC cells. The prospect of integrating aerobic exercise-based metabolic modulation with pharmacological agents targeting CNDP2 or amino acid metabolism signals a promising horizon for personalized oncology.

Translational aspects of this research are equally compelling. From a clinical standpoint, these insights justify the incorporation of structured exercise programs into therapeutic protocols for ccRCC patients and possibly beyond. Tailoring exercise prescriptions to optimize lactate production and CNDP2 activation may not only improve patient outcomes by directly curtailing tumor growth but also enhance overall well-being through well-established systemic benefits.

Importantly, the study also highlights the sophisticated interplay between tumor microenvironment and systemic metabolism. Exercise-induced lactate circulates in the bloodstream, affecting not only local muscle tissue but distant organs, including tumors. Hence, the tumor microenvironment must be understood in a systemic context, where metabolic cues from physical activity orchestrate cellular processes that either fuel or frustrate malignancy.

The research narrative delves into cellular energetics, showing that intracellular amino acid depletion caused by CNDP2 impairs protein synthesis, redox balance, and nucleotide turnover—a triad integral to cancer cell survival. By undermining these biosynthetic pathways, CNDP2 effectively compromises cellular resilience, pushing ccRCC cells toward metabolic crisis. This mechanistic depth enriches our comprehension of how subtle shifts in nutrient flux can precipitate profound effects on tumor fate.

Further strengthening their conclusions, the investigators confirmed the presence of CNDP2-mediated effects in patient-derived ccRCC tissues, suggesting clinical relevance beyond experimental models. This translational validation offers a feasible biomarker for gauging tumor responsiveness to exercise-linked metabolic interventions and possibly stratifying patients for targeted therapeutic combinations.

The discovery also spurs questions about the specificity of this mechanism. Does CNDP2-driven intracellular amino acid depletion apply uniquely to ccRCC, or might it exert influence across other tumor types with similar metabolic phenotypes? Given the heterogeneity of tumor metabolism, future research into CNDP2’s role in broader oncological contexts could reveal new therapeutic avenues or unforeseen resistance mechanisms.

Taken together, this pioneering study eloquently intertwines disciplines of exercise physiology, metabolism, and oncology, igniting a paradigm shift that reframes how we perceive the interface of lifestyle and cancer biology. It underscores the profound impact of metabolic modulation through endogenous molecules like lactate, advocating a more integrative approach to cancer treatment that harmonizes patient lifestyle, molecular biology, and therapeutic innovation.

In an era where personalized medicine is rapidly advancing, such revelations emphasize the necessity to consider physical activity not merely as a supportive element but as a potent biological modifier capable of reconfiguring tumor cell fate. The strategic harnessing of exercise-induced metabolic shifts offers an inspiring blueprint for future research and clinical translation in the fight against ccRCC and potentially other stubborn malignancies.

As the scientific community continues to unravel the complex metabolic tapestries that sustain cancer, findings like these serve as a beacon illuminating the untapped potential lying within our own physiology. Exercise, often touted for its holistic health benefits, emerges here as a formidable biochemical weapon, wielded through the metabolic enzyme CNDP2 and its consequential reshaping of the tumor intracellular environment. This research invites a fresh and hopeful perspective—that the cure to some cancers might lie, at least in part, in the cadence of our own breath and the rhythm of our movement.

Subject of Research: The molecular mechanisms by which exercise-induced lactate suppresses clear cell renal cell carcinoma (ccRCC) through CNDP2-mediated depletion of intracellular amino acids.

Article Title: Exercise-induced lactate suppresses ccRCC via CNDP2-mediated depletion of intracellular amino acids.

Article References:
Miao, R., Liu, C., Wang, Y. et al. Exercise-induced lactate suppresses ccRCC via CNDP2-mediated depletion of intracellular amino acids. Cell Death Discov. 11, 356 (2025). https://doi.org/10.1038/s41420-025-02609-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02609-3